Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (23)

2023

  1. TNAP and P2X7R: New Plasma Biomarkers for Alzheimer’s Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 13

2022

  1. TNAP upregulation is a critical factor in Tauopathies and its blockade ameliorates neurotoxicity and increases life-expectancy

    Neurobiology of Disease, Vol. 165

2021

  1. Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation

    Molecular Psychiatry, Vol. 26, Núm. 11, pp. 6411-6426

2020

  1. Differential regulation of Kidins220 isoforms in Huntington's disease

    Brain Pathology, Vol. 30, Núm. 1, pp. 120-136

2019

  1. Peripheral nervous system effects in the PS19 tau transgenic mouse model of tauopathy

    Neuroscience Letters, Vol. 698, pp. 204-208

2018

  1. Erratum: Author Correction: Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1 (Nature communications (2017) 8 1 (2275))

    Nature communications

  2. The neurotoxic role of extracellular tau protein

    International Journal of Molecular Sciences, Vol. 19, Núm. 4

  3. The regulation of proteostasis in glial cells by nucleotide receptors is key in acute neuroinflammation

    FASEB Journal, Vol. 32, Núm. 6, pp. 3020-3032

2017

  1. Regulation of proteasome activity by P2Y2 receptor underlies the neuroprotective effects of extracellular nucleotides

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1863, Núm. 1, pp. 43-51

2016

  1. Presynaptic P2X1-3 and α3-containing nicotinic receptors assemble into functionally interacting ion channels in the rat hippocampus

    Neuropharmacology, Vol. 105, pp. 241-257

2015

  1. TNAP plays a key role in neural differentiation as well as in neurodegenerative disorders

    Sub-Cellular Biochemistry, Vol. 76, pp. 375-385

2014

  1. Epitope mapping of antibodies to alpha-synuclein in LRRK2 mutation carriers, idiopathic parkinson disease patients, and healthy controls

    Frontiers in Aging Neuroscience, Vol. 6, Núm. JUL

  2. Sources of extracellular tau and its signaling

    Journal of Alzheimer's Disease, Vol. 40, Núm. S1

2012

  1. In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases

    Neurobiology of Aging, Vol. 33, Núm. 8, pp. 1816-1828

  2. Looking for novel functions of tau

    Biochemical Society Transactions

  3. Tau overexpression results in its secretion via membrane vesicles

    Neurodegenerative Diseases, Vol. 10, Núm. 1-4, pp. 73-75

  4. α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease

    Human Molecular Genetics, Vol. 21, Núm. 3, pp. 495-510

2010

  1. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum

    Cell Death and Differentiation, Vol. 17, Núm. 2, pp. 324-335

  2. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau

    Journal of Biological Chemistry, Vol. 285, Núm. 42, pp. 32539-32548

2009

  1. Ca2+/calmodulin-dependent kinase II signalling cascade mediates P2X7 receptor-dependent inhibition of neuritogenesis in neuroblastoma cells

    FEBS Journal, Vol. 276, Núm. 18, pp. 5307-5325